All lobbying filings

SOLVENTUM CORPORATION

SOLVENTUM CORPORATION filed a Q1 report for SOLVENTUM CORPORATION on April 20, 2026.

Lobbying for SOLVENTUM CORPORATION

All filings by SOLVENTUM CORPORATION · Everything SOLVENTUM CORPORATION has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$250,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Utah

Official filing document

Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Health Issues

-Issues related to regulation of Ethylene Oxide (EtO). -Issues related to access to sterilization capacity for medical technologies. -Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act 21st Century Cures Act (PL 114-255). -Regulations and legislation related to International Classification of Diseases, version 10 (ICD-10). -Healthcare Outcomes Act. -Issues related to the use of Artificial Intelligence. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to CY 2026 Home Health Prospective Payment System (HH PPS) Rate Update and DMEPOS.

Medicare/Medicaid

-Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act 21st Century Cures Act (PL 114-255). -Regulations and legislation related to International Classification of Diseases, Version 10 (ICD-10). -Healthcare Outcomes Act. -Issues related to the use of Artificial Intelligence. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to CY 2026 Home Health Prospective Payment System (HH PPS) Rate Update and DMEPOS.

Defense

-Issues related to Department of Defense policy, procurement, and contracting processes for medical technology. -Issues related to H.R. 1 implementation (One Big Beautiful Bill).

Trade (domestic/foreign)

-Issues related to domestic and global medical supply chain resilience. -Tariff issues generally. -Issues related to the 232 investigation of imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices.

Veterans

Issues related to Veterans Administration and Veterans Health Administration policy, procurement, and contracting processes for medical technology.

Bills named in this filing 1

H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.